Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

NICE recommends nivolumab plus ipilimumab for untreated advanced kidney cancer in intermediate or poor-risk patients - ecancer

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

ICU :: Investigative and Clinical Urology

Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer - European Urology Focus

Castration Resistant Prostate Cancer: Developments & Challenges in 2020

Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis

Management of Castration-Resistant Prostate Cancer

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial - ScienceDirect

JPM, Free Full-Text

Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) - The Lancet Oncology

A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer